TY - JOUR
T1 - CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma
T2 - Individual Patient Data Meta-Analysis
AU - van der Pol, Christian B.
AU - McInnes, Matthew D.F.
AU - Salameh, Jean Paul
AU - Levis, Brooke
AU - Chernyak, Victoria
AU - Sirlin, Claude B.
AU - Bashir, Mustafa R.
AU - Allen, Brian C.
AU - Burke, Lauren M.B.
AU - Choi, Jin Young
AU - Choi, Sang Hyun
AU - Forner, Alejandro
AU - Fraum, Tyler J.
AU - Giamperoli, Alice
AU - Jiang, Hanyu
AU - Joo, Ijin
AU - Kang, Zhen
AU - Kierans, Andrea S.
AU - Kang, Hyo Jin
AU - Khatri, Gaurav
AU - Kim, Jung Hoon
AU - Kim, Myeong Jin
AU - Kim, So Yeon
AU - Kim, Yeun Yoon
AU - Kwon, Heejin
AU - Lee, Jeong Min
AU - Lewis, Sara C.
AU - McGinty, Katrina A.
AU - Mulazzani, Lorenzo
AU - Park, Mi Suk
AU - Piscaglia, Fabio
AU - Podgórska, Joanna
AU - Reiner, Caecilia S.
AU - Ronot, Maxime
AU - Rosiak, Grzegorz
AU - Song, Bin
AU - Song, Ji Soo
AU - Tang, An
AU - Terzi, Eleonora
AU - Wang, Jin
AU - Wang, Wei
AU - Wilson, Stephanie R.
AU - Yokoo, Takeshi
N1 - Funding Information:
Disclosures of conflicts of interest: C.B.v.d.P. Disclosed no relevant relationships. M.D.F.M. Disclosed no relevant relationships. J.P.S. Disclosed no relevant relationships. B.L. Disclosed no relevant relationships. V.C. Consulting fees from Bayer, Bayer advisory board, chair of the LI-RADS Steering Committee. C.B.S. Grants from GE, Siemens, Philips, Bayer, Foundation of NIH, Gilead, and Pfizer (grant is to UW-Madison; UCSD is a subcontract to UW-Madison), Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; royalties from Wolt-ers Kluwer for educational material outside the submitted work; consultation fees from Blade, Boehringer, and Epigenomics; consultation under the auspices of the University to AMRA, BMS, Exact Sciences, GE Digital, IBM-Watson, and Pfizer; honoraria to the institution from Medscape for educational material outside the submitted work; stock options in Livivos; Quantix Bio advisory board. M.R.B. Grants from Carmot Therapeutics, Corcept Therapeutics, CymaBay Therapeutics, Diabetes and Endocrinology Consultants, NGM Biopharmaceuticals, Madrigal Pharmaceuticals, Metacrine, Pinnacle Clinical Research, Polarean, ProSciento, and Siemens Healthineers; grants from Correct Therapeutics, ICON, and MedPace. B.C.A. disclosed no relevant relationships. L.M.B.B. Seminars for Roentgenology; expert testimony for Fadell, Cheney, and Burt. J.Y.C. Disclosed no relevant relationships. S.H.C. Research funding from and on the advisory board of Bayer Korea. A.F. Consulting fees from Bayer, AstraZeneca, Roche, Exact Science, and Guerbert; lecture fees from Bayer, Boston, Gilead, and Merck. T.J.F. Disclosed no relevant relationships. A.G. Disclosed no relevant relationships. H.J. Disclosed no relevant relationships. I.J. Disclosed no relevant relationships. Z.K. Disclosed no relevant relationships. A.S.K. Disclosed no relevant relationships. H.J.K. Disclosed no relevant relationships. G.K. Disclosed no relevant relationships. J.H.K. Disclosed no relevant relationships. M.J.K. Disclosed no relevant relationships. S.Y.K. Disclosed no relevant relationships. Y.Y.K. Disclosed no relevant relationships. H.K. Disclosed no relevant relationships. J.M.L. Grants from Bayer, GE Healthcare, Gerbett, Bracco, Central Medical Service, Stardmed, RF Medical, Canon Korea, Samsung Medison, Dongkug Pharma, and Vuno; lectures for Bayer, GE Healthcare, Samsung Medison, Starmed, and RF Medical. S.C.L. Disclosed no relevant relationships. K.A.M. Disclosed no relevant relationships. L.M. Disclosed no relevant relationships. M.S.P. Disclosed no relevant relationships. F.P. Departmental contracts with ESAOTE for cooperative research purposes and with Bracco for consultancy; honoraria from GE and Bracco for serving as a consultant; honoraria from Astrazeneca, Bayer, EISAI, IPSEN, MSD, BMS, and Samsung for lectures or presentations; honoraria from Astrazeneca, Roche, Alkermes, Tiziana Life Sciences EISAI, IPSEN, and MSD for attending advisory boards; member of the governing board of the International Contrast Ultrasound Society. J.P. Disclosed no relevant relationships. C.S.R. Disclosed no relevant relationships. M.R. Disclosed no relevant relationships. G.R. Disclosed no relevant relationships. B.S. Disclosed no relevant relationships. J.S.S. Disclosed no relevant relationships. A.T. Honoraria from Eli Lilly and Siemens Healthineers; former chair of the LI-RADS International Working Group. E.T. Disclosed no relevant relationships. J.W. Disclosed no relevant relationships. W.W. Disclosed no relevant relationships. S.R.W. Partial research support from Samsung for an unrelated project; equipment support from Samsung, Siemens, and Philips. T.Y. Consulting fees from ABC Medical Education.
Funding Information:
Supported by a grant from the Joan Sealy Trust for Cancer Research, a Fonds de Recherche du Québec–Santé postdoctoral training fellowship (B.L.), the Sichuan Province Science and Technology Support Program (2021YFS0141) (H.J.), and the Fonds de Recherche du Québec–Santé and Fondation de l’Association des Radiologistes du Québec (34939, 298509) (A.T.).
Funding Information:
Supported by a grant from the Joan Sealy Trust for Cancer Research, a Fonds de Recherche du Qu?bec-Sant? postdoctoral training fellowship (B.L.), the Sichuan Province Science and Technology Support Program (2021YFS0141) (H.J.), and the Fonds de Recherche du Qu?bec-Sant? and Fondation de l'Association des Radiologistes du Qu?bec (34939, 298509) (A.T.).
Publisher Copyright:
© RSNA, 2021
PY - 2022/2
Y1 - 2022/2
N2 - Background: The Liver Imaging Reporting and Data System (LI-RADS) assigns a risk category for hepatocellular carcinoma (HCC) to imaging observations. Establishing the contributions of major features can inform the diagnostic algorithm. Purpose: To perform a systematic review and individual patient data meta-analysis to establish the probability of HCC for each LIRADS major feature using CT/MRI and contrast-enhanced US (CEUS) LI-RADS in patients at high risk for HCC. Materials and Methods: Multiple databases (MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus) were searched for studies from January 2014 to September 2019 that evaluated the accuracy of CT, MRI, and CEUS for HCC detection using LI-RADS (CT/MRI LI-RADS, versions 2014, 2017, and 2018; CEUS LI-RADS, versions 2016 and 2017). Data were centralized. Clustering was addressed at the study and patient levels using mixed models. Adjusted odds ratios (ORs) with 95% CIs were determined for each major feature using multivariable stepwise logistic regression. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) (PROSPERO protocol: CRD42020164486). Results: A total of 32 studies were included, with 1170 CT observations, 3341 MRI observations, and 853 CEUS observations. At multivariable analysis of CT/MRI LI-RADS, all major features were associated with HCC, except threshold growth (OR, 1.6; 95% CI: 0.7, 3.6; P =.07). Nonperipheral washout (OR, 13.2; 95% CI: 9.0, 19.2; P =.01) and nonrim arterial phase hyperenhancement (APHE) (OR, 10.3; 95% CI: 6.7, 15.6; P =.01) had stronger associations with HCC than enhancing capsule (OR, 2.4; 95% CI: 1.7, 3.5; P =.03). On CEUS images, APHE (OR, 7.3; 95% CI: 4.6, 11.5; P =.01), late and mild washout (OR, 4.1; 95% CI: 2.6, 6.6; P =.01), and size of at least 20 mm (OR, 1.6; 95% CI: 1.04, 2.5; P =.04) were associated with HCC. Twenty-five studies (78%) had high risk of bias due to reporting ambiguity or study design flaws. Conclusion: Most Liver Imaging Reporting and Data System major features had different independent associations with hepatocellular carcinoma; for CT/MRI, arterial phase hyperenhancement and washout had the strongest associations, whereas threshold growth had no association.
AB - Background: The Liver Imaging Reporting and Data System (LI-RADS) assigns a risk category for hepatocellular carcinoma (HCC) to imaging observations. Establishing the contributions of major features can inform the diagnostic algorithm. Purpose: To perform a systematic review and individual patient data meta-analysis to establish the probability of HCC for each LIRADS major feature using CT/MRI and contrast-enhanced US (CEUS) LI-RADS in patients at high risk for HCC. Materials and Methods: Multiple databases (MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Scopus) were searched for studies from January 2014 to September 2019 that evaluated the accuracy of CT, MRI, and CEUS for HCC detection using LI-RADS (CT/MRI LI-RADS, versions 2014, 2017, and 2018; CEUS LI-RADS, versions 2016 and 2017). Data were centralized. Clustering was addressed at the study and patient levels using mixed models. Adjusted odds ratios (ORs) with 95% CIs were determined for each major feature using multivariable stepwise logistic regression. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) (PROSPERO protocol: CRD42020164486). Results: A total of 32 studies were included, with 1170 CT observations, 3341 MRI observations, and 853 CEUS observations. At multivariable analysis of CT/MRI LI-RADS, all major features were associated with HCC, except threshold growth (OR, 1.6; 95% CI: 0.7, 3.6; P =.07). Nonperipheral washout (OR, 13.2; 95% CI: 9.0, 19.2; P =.01) and nonrim arterial phase hyperenhancement (APHE) (OR, 10.3; 95% CI: 6.7, 15.6; P =.01) had stronger associations with HCC than enhancing capsule (OR, 2.4; 95% CI: 1.7, 3.5; P =.03). On CEUS images, APHE (OR, 7.3; 95% CI: 4.6, 11.5; P =.01), late and mild washout (OR, 4.1; 95% CI: 2.6, 6.6; P =.01), and size of at least 20 mm (OR, 1.6; 95% CI: 1.04, 2.5; P =.04) were associated with HCC. Twenty-five studies (78%) had high risk of bias due to reporting ambiguity or study design flaws. Conclusion: Most Liver Imaging Reporting and Data System major features had different independent associations with hepatocellular carcinoma; for CT/MRI, arterial phase hyperenhancement and washout had the strongest associations, whereas threshold growth had no association.
UR - http://www.scopus.com/inward/record.url?scp=85124489189&partnerID=8YFLogxK
U2 - 10.1148/RADIOL.2021211244
DO - 10.1148/RADIOL.2021211244
M3 - Article
C2 - 34783596
AN - SCOPUS:85124489189
SN - 0033-8419
VL - 302
SP - 326
EP - 335
JO - Radiology
JF - Radiology
IS - 2
ER -